| Liprin Protein | |
|---|---|
| Gene | [PPFIA1](/genes/ppfia1) |
| UniProt | Q13136 |
| PDB | 5E45 |
| Mol. Weight | 175 kDa |
| Localization | Presynaptic active zone, [dendritic spines](/mechanisms/dendritic-spines), postsynaptic density |
| Family | Liprin family, LAR-RPTP interacting proteins |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als) |
Liprin Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Liprin (also known as Liprin-alpha or LAR-RPTP interacting protein) is a family of scaffolding proteins that play essential roles in synapse development, function, and plasticity[1]. The liprin family consists of multiple isoforms (liprin-alpha1-4 and liprin-beta), each with distinct expression patterns and functions[2].
The PPFIA1 gene encodes liprin-alpha1, the founding member of the family. Liprins are characterized by their ability to interact with LAR (Leukocyte common antigen-related) receptor protein tyrosine phosphatases and their role in orchestrating synaptic protein complexes[3].
Liprin proteins contain multiple protein-interacting domains:
The N-terminal region contains coiled-coil motifs that mediate homomeric and heteromeric dimerization between liprin family members.
The central region contains the critical LAR-RPTP binding domain, which is essential for liprin's synaptic functions.
The C-terminal region contains sterile alpha motif (SAM) domains that mediate additional protein-protein interactions[4].
Liprin plays critical roles in excitatory synapse development:
In the presynaptic terminal, liprin interacts with:
Liprins mediate synaptic adhesion by bridging presynaptic and postsynaptic proteins, ensuring proper synaptic contact formation and maintenance[^5].
Liprin-alpha is involved in amyloid precursor protein (APP) processing and may modulate amyloid-beta production. Changes in liprin expression have been observed in AD brains[^6].
Liprin interactions with synaptic proteins may be altered in PD, affecting dopaminergic synapse function and stability[^7].
Mutations in liprin-related genes have been implicated in some cases of ALS, highlighting the importance of synaptic scaffolding in motor neuron disease[^8].
Therapeutic approaches include:
The study of Liprin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Serra-Pagès et al. Liprin: a novel LAR-interacting protein (1995). 1995. ↩︎
Ko et al. [Liprin in synapse development (2003)](https://doi.org/10.1016/S0896-6273(03). 2003. ↩︎
Wentzel et al. Liprin and PSD organization (2013). 2013. ↩︎
Siksou et al. Liprin at the active zone (2017). 2017. ↩︎